SINO BIOPHARM (01177) signed an exclusive strategic cooperation agreement with Sinobioway Biotechnology regarding the IL-29 project.

SINO BIOPHARM (01177) announced that CPX102 is an inhalable solution optimized through protein engineering based on IL-29, which belongs to type III interferons. The group is currently conducting phase IIb clinical trials in China for this project, which is used to treat respiratory syncytial virus (RSV) infections in children. CPX102 does not directly kill or inhibit the virus, but rather induces cell surface receptors to promote the production of antiviral proteins in cells, thereby inhibiting viral replication. In addition, CPX102 can also regulate immune cells such as cytotoxic T lymphocytes (CTL cells), natural killer cells (NK cells), and macrophages, activating the body's natural immunity and playing a role in antiviral defense.